Exploiting mesoporous silica, silver and gold nanoparticles for neurodegenerative diseases treatment

被引：16

作者：

Ribeiro, Tais C. ^{[1
]}

Sabio, Rafael M. ^{[1
]}

Carvalho, Gabriela C. ^{[1
]}

Fonseca-Santos, Bruno ^{[2
]}

Chorilli, Marlus ^{[1
]}

机构：

[1] Sao Paulo State Univ, Sch Pharmaceut Sci, Dept Drugs & Med, BR-14801903 Araraquara, SP, Brazil

[2] Univ Fed Bahia, Dept Biotechnol, Hlth Sci Inst, Salvador, BA, Brazil

来源：

INTERNATIONAL JOURNAL OF PHARMACEUTICS | 2022年 / 624卷

基金：

巴西圣保罗研究基金会;

关键词：

Mesoporous silica nanoparticles; Silver and gold nanoparticles; Smart nanocarriers; Drug delivery systems; Neurodegenerative diseases treatment; CONTROLLED-RELEASE SYSTEM; ALZHEIMERS-DISEASE; DRUG-DELIVERY; OXIDATIVE STRESS; IN-VITRO; METAL NANOPARTICLES; PARKINSONS-DISEASE; MUCUNA-PRURIENS; BRAIN; SIZE;

D O I：

10.1016/j.ijpharm.2022.121978

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Neurodegenerative diseases (NDs) are considered public health problem characterized by neural loss causing cognitive and behavioral impairments. It is currently possible to use drugs capable of controlling the symptoms caused by these diseases. However, treatment is not able to prevent neural loss. In addition, poor solubility, low bioavailability due to the inability for crossing the blood-brain barrier (BBB) are described as the main limitations of the treatment. Nanotechnology involves the development of nanoscale drug delivery systems and they have been employed to optimize therapeutics face to several diseases treatment. In light of this, this review describes the highlights on the fabrication of nanotechnology-based drug delivery systems emphasizing mesoporous silica, gold and silver nanoparticles (MSNs, AuNPs and AgNPs, respectively) and their biological behavior for the treatment of Alzheimer's and Parkinson diseases (ADs and PDs, respectively).

引用

页数：16

共 203 条

[1] Recent advances in stimuli-responsive drug release and targeting concepts using mesoporous silica nanoparticles [J].

Abdo, Ghada G. ;

Zagho, Moustafa M. ;

Khalil, Ashraf .

EMERGENT MATERIALS, 2020, 3 (03) :407-425

[2] Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia [J].

Ahmad, Niyaz ;

Ahmad, Rizwan ;

Ahmad, Farhan Jalees ;

Ahmad, Wasim ;

Alam, Md Aftab ;

Amir, Mohd ;

Ali, Abuzer .

SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2020, 27 (01) :500-517

[3] High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases [J].

Aldewachi, Hasan ;

Al-Zidan, Radhwan N. ;

Conner, Matthew T. ;

Salman, Mootaz M. .

BIOENGINEERING-BASEL, 2021, 8 (02) :1-20

[4] Anthocyanin-Loaded PEG-Gold Nanoparticles Enhanced the Neuroprotection of Anthocyanins in an Aβ1-42 Mouse Model of Alzheimer's Disease [J].

Ali, Tahir ;

Kim, Min Ju ;

Rehman, Shafiq Ur ;

Ahmad, Ashfaq ;

Kim, Myeong Ok .

MOLECULAR NEUROBIOLOGY, 2017, 54 (08) :6490-6506

[5] Influences of material characteristics on ibuprofen drug loading and release profiles from ordered micro- and mesoporous silica matrices [J].

Andersson, J ;

Rosenholm, J ;

Areva, S ;

Lindén, M .

CHEMISTRY OF MATERIALS, 2004, 16 (21) :4160-4167

[6] 2021 Alzheimer's disease facts and figures [J].

不详 .

ALZHEIMERS & DEMENTIA, 2021, 17 (03) :327-406

[7]

[Anonymous], 2004, NANOSCIENCE NANOTECH

[8] Tau and tauopathies [J].

Arendt, Thomas ;

Stieler, Jens T. ;

Holzer, Max .

BRAIN RESEARCH BULLETIN, 2016, 126 :238-292

[9] Diagnosis and Treatment of Parkinson Disease A Review [J].

Armstrong, Melissa J. ;

Okun, Michael S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (06) :548-560

[10]

Arulkumar S., 2010, Int. J. Res. Pharm. Sci, V1, P417

← 1 2 3 4 5 6 7 8 9 10 →